Yader Sandoval1,2,3, Stephen W Smith3,4, Anoop S V Shah5, Atul Anand5, Andrew R Chapman5, Sara A Love3,6, Karen Schulz3, Jing Cao3, Nicholas L Mills5, Fred S Apple7,6. 1. Division of Cardiology, Hennepin County Medical Center, Minneapolis, MN. 2. Minneapolis Heart Institute, Abbott-Northwestern Hospital, Minneapolis, MN. 3. Minneapolis Medical Research Foundation, Minneapolis, MN. 4. Department of Emergency Medicine, Hennepin County Medical Center and University of Minnesota, MN. 5. BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK. 6. Department of Laboratory Medicine and Pathology, Hennepin County Medical Center and University of Minnesota, Minneapolis, MN. 7. Minneapolis Medical Research Foundation, Minneapolis, MN; apple004@umn.edu.
Abstract
BACKGROUND: Rapid rule-out strategies using high-sensitivity cardiac troponin assays are largely supported by studies performed outside the US in selected cohorts of patients with chest pain that are atypical of US practice, and focused exclusively on ruling out acute myocardial infarction (AMI), rather than acute myocardial injury, which is more common and associated with a poor prognosis. METHODS: Prospective, observational study of consecutive patients presenting to emergency departments [derivation (n = 1647) and validation (n = 2198) cohorts], where high-sensitivity cardiac troponin I (hs-cTnI) was measured on clinical indication. The negative predictive value (NPV) and diagnostic sensitivity of an hs-cTnI concentration <limit of detection (LoD) at presentation was determined for acute myocardial injury and for AMI or cardiac death at 30 days. RESULTS: In patients with hs-cTnI concentrations <99th percentile at presentation, acute myocardial injury occurred in 8.3% and 11.0% in the derivation and validation cohorts, respectively. In the derivation cohort, 27% had hs-cTnI < LoD, with NPV and diagnostic sensitivity for acute myocardial injury of 99.1% (95% CI, 97.7-99.8) and 99.0% (97.5-99.7) and an NPV for AMI or cardiac death at 30 days of 99.6% (98.4-100). In the validation cohort, 22% had hs-cTnI <LoD, with an NPV and diagnostic sensitivity for acute myocardial injury of 98.8% (97.9-99.7) and 99.3% (98.7-99.8) and an NPV for AMI or cardiac death at 30 days of 99.1% (98.2-99.8). CONCLUSIONS: A single hs-cTnI concentration <LoD rules out acute myocardial injury, regardless of etiology, with an excellent NPV and diagnostic sensitivity, and identifies patients at minimal risk of AMI or cardiac death at 30 days. ClinicalTrials.gov Identifier: NCT02060760.
BACKGROUND: Rapid rule-out strategies using high-sensitivity cardiac troponin assays are largely supported by studies performed outside the US in selected cohorts of patients with chest pain that are atypical of US practice, and focused exclusively on ruling out acute myocardial infarction (AMI), rather than acute myocardial injury, which is more common and associated with a poor prognosis. METHODS: Prospective, observational study of consecutive patients presenting to emergency departments [derivation (n = 1647) and validation (n = 2198) cohorts], where high-sensitivity cardiac troponin I (hs-cTnI) was measured on clinical indication. The negative predictive value (NPV) and diagnostic sensitivity of an hs-cTnI concentration <limit of detection (LoD) at presentation was determined for acute myocardial injury and for AMI or cardiac death at 30 days. RESULTS: In patients with hs-cTnI concentrations <99th percentile at presentation, acute myocardial injury occurred in 8.3% and 11.0% in the derivation and validation cohorts, respectively. In the derivation cohort, 27% had hs-cTnI < LoD, with NPV and diagnostic sensitivity for acute myocardial injury of 99.1% (95% CI, 97.7-99.8) and 99.0% (97.5-99.7) and an NPV for AMI or cardiac death at 30 days of 99.6% (98.4-100). In the validation cohort, 22% had hs-cTnI <LoD, with an NPV and diagnostic sensitivity for acute myocardial injury of 98.8% (97.9-99.7) and 99.3% (98.7-99.8) and an NPV for AMI or cardiac death at 30 days of 99.1% (98.2-99.8). CONCLUSIONS: A single hs-cTnI concentration <LoD rules out acute myocardial injury, regardless of etiology, with an excellent NPV and diagnostic sensitivity, and identifies patients at minimal risk of AMI or cardiac death at 30 days. ClinicalTrials.gov Identifier: NCT02060760.
Authors: Dirk Westermann; Johannes Tobias Neumann; Nils Arne Sörensen; Stefan Blankenberg Journal: Nat Rev Cardiol Date: 2017-04-06 Impact factor: 32.419
Authors: Yader Sandoval; Bradley R Lewis; Ramila A Mehta; Olatunde Ola; Jonathan D Knott; Laura De Michieli; Ashok Akula; Ronstan Lobo; Eric H Yang; S Michael Gharacholou; Marshall Dworak; Erika Crockford; Nicholas Rastas; Eric Grube; Swetha Karturi; Scott Wohlrab; David O Hodge; Tahir Tak; Charles Cagin; Rajiv Gulati; Allan S Jaffe Journal: Circulation Date: 2022-05-10 Impact factor: 39.918
Authors: Ian Gunsolus; Yader Sandoval; Stephen W Smith; Anne Sexter; Karen Schulz; Charles A Herzog; Fred S Apple Journal: J Am Soc Nephrol Date: 2017-10-27 Impact factor: 10.121
Authors: Anda Bularga; Kuan Ken Lee; Stacey Stewart; Amy V Ferry; Andrew R Chapman; Lucy Marshall; Fiona E Strachan; Anne Cruickshank; Donogh Maguire; Colin Berry; Iain Findlay; Anoop S V Shah; David E Newby; Nicholas L Mills; Atul Anand Journal: Circulation Date: 2019-09-01 Impact factor: 29.690
Authors: Rosanna Inzitari; Sebastian Vencken; David Daghfal; Karl McAuley; Anthony McDermott; Marie Galligan; Peter Doran Journal: Pract Lab Med Date: 2021-03-26
Authors: Eve Miller-Hodges; Atul Anand; Anoop S V Shah; Andrew R Chapman; Peter Gallacher; Kuan Ken Lee; Tariq Farrah; Nynke Halbesma; James P Blackmur; David E Newby; Nicholas L Mills; Neeraj Dhaun Journal: Circulation Date: 2017-10-04 Impact factor: 29.690
Authors: Anoop S V Shah; Yader Sandoval; Ala Noaman; Anne Sexter; Amar Vaswani; Stephen W Smith; Mathew Gibbins; Megan Griffiths; Andrew R Chapman; Fiona E Strachan; Atul Anand; Martin A Denvir; Philip D Adamson; Michelle S D'Souza; Alasdair J Gray; David A McAllister; David E Newby; Fred S Apple; Nicholas L Mills Journal: BMJ Date: 2017-11-07
Authors: Ryan Wereski; Dorien M Kimenai; Caelan Taggart; Dimitrios Doudesis; Kuan Ken Lee; Matthew T H Lowry; Anda Bularga; David J Lowe; Takeshi Fujisawa; Fred S Apple; Paul O Collinson; Atul Anand; Andrew R Chapman; Nicholas L Mills Journal: Circulation Date: 2021-06-25 Impact factor: 29.690